A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors.

Patients with multi-site cancers demonstrated a notably higher cumulative incidence of irAEs compared to melanoma patients, with the difference being highly significant ( P = 0.0000546).

also in 132,142 other papers

Liver disease was prevalent in 29.2% of irAE patients and 27.1% of non-irAE patients, with a P -value of 0.058, indicating a trend towards significance.

also in 2,760 other papers

While trends favored longer irAE-free intervals with monotherapy, differences did not reach statistical significance, suggesting a more limited influence of regimen on irAE timing in these tumor types.

also in 111,027 other papers